Summary:
- Zolgensma, a gene therapy drug developed by Novartis, is the most expensive drug in the world, costing $2.1 million for a one-time treatment.
- The drug is used to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disorder that affects the motor neurons, leading to muscle weakness and progressive loss of movement.
- The high cost of Zolgensma has raised concerns about access and affordability, with many families struggling to obtain the treatment due to insurance coverage limitations and the financial burden on healthcare systems.